No Data
No Data
Merck to Build $1B Delaware Plant to Ensure Domestic Supply of Keytruda - Report
Warren Buffett's 60-Year Legacy: What to Watch for at Berkshire Hathaway Shareholders Meeting?
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!
Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
loading...